Thus, targeting antiapoptotic BCL-2 family proteins may be an emerging therapeutic strategy for patients with cisplatin-resistant ovarian cancer since it allows the induction of DRP1-dependent apoptotic mitochondrial fission [66,88]. Here, DNM1L is linked to ovarian cancer.